Statements (36)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2011 |
| gptkbp:ATCCode |
L01XE12
|
| gptkbp:brand |
gptkb:Caprelsa
|
| gptkbp:CASNumber |
443913-73-3
|
| gptkbp:contraindication |
gptkb:congenital_long_QT_syndrome
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:eliminationHalfLife |
19 days
|
| gptkbp:hasMolecularFormula |
C22H24BrFN4O
|
| https://www.w3.org/2000/01/rdf-schema#label |
vandetanib
|
| gptkbp:KEGGID |
D08913
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
475.36 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201197
3081369 DB05868 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
hypertension rash QT prolongation |
| gptkbp:synonym |
ZD6474
|
| gptkbp:target |
gptkb:EGFR
gptkb:VEGFR gptkb:RET |
| gptkbp:UNII |
Q1J0S2TZ5A
|
| gptkbp:usedFor |
medullary thyroid cancer
|
| gptkbp:bfsParent |
gptkb:RET
gptkb:RET_proto-oncogene |
| gptkbp:bfsLayer |
5
|